Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma

Chengwen Zhang, Benjamin Beckermann, Georgios Kallifatidis, Zheng Liu, Werner Rittgen, Lutz Edler, Peter Büchler, Klaus Michael Debatin, Markus W. Büchler, Helmut Friess, Ingrid Herr

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Glucocorticoids (GCs) such as dexamethasone (DEX) have been widely used as co-medication in cancer therapy because they have potent proapoptotic properties in lymphoid cells, can reduce nausea, and alleviate acute toxic effects in healthy tissue. However, GCs are used in a supportive-care role, even though no prospective clinical studies have assessed the effect of these steroids on the growth of solid tumours. Data from preclinical and, to some extent, clinical studies, suggest that GCs induce treatment resistance in some solid tumours. Since it is unknown whether GC-induced resistance occurs only occasionally or is a more common phenomenon, we performed a screening study using several established cell lines from bone, brain, breast and cervix carcinoma as well as melanoma and neuroblastoma together with fresh surgical resections from patients with breast cancer. We found that DEX inhibits cisplatin and 5-fluorouracil-induced apoptosis and promotes the growth of the majority of examined malignant cells. In contrast, and as expected, DEX acted pro-apoptotically and promoted the cytotoxic effect of chemotherapy in established and primary lymphoid cells. Thus, these data demonstrate the need for detailed molecular studies to clarify the mechanism of differential glucocorticoid signaling as well as controlled, prospective clinical studies.

Original languageEnglish (US)
Pages (from-to)1295-1301
Number of pages7
JournalInternational Journal of Oncology
Volume29
Issue number5
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Neuroblastoma
Cervix Uteri
Glucocorticoids
Melanoma
Adrenal Cortex Hormones
Breast
Dexamethasone
Bone and Bones
Drug Therapy
Brain
Neoplasms
Prospective Studies
Lymphocytes
Breast Neoplasms
Poisons
Growth
Fluorouracil
Nausea
Cisplatin
Steroids

Keywords

  • Apoptosis
  • Cancer therapy
  • Glucocorticoids
  • Nausea

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. / Zhang, Chengwen; Beckermann, Benjamin; Kallifatidis, Georgios; Liu, Zheng; Rittgen, Werner; Edler, Lutz; Büchler, Peter; Debatin, Klaus Michael; Büchler, Markus W.; Friess, Helmut; Herr, Ingrid.

In: International Journal of Oncology, Vol. 29, No. 5, 01.11.2006, p. 1295-1301.

Research output: Contribution to journalArticle

Zhang, C, Beckermann, B, Kallifatidis, G, Liu, Z, Rittgen, W, Edler, L, Büchler, P, Debatin, KM, Büchler, MW, Friess, H & Herr, I 2006, 'Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma', International Journal of Oncology, vol. 29, no. 5, pp. 1295-1301.
Zhang, Chengwen ; Beckermann, Benjamin ; Kallifatidis, Georgios ; Liu, Zheng ; Rittgen, Werner ; Edler, Lutz ; Büchler, Peter ; Debatin, Klaus Michael ; Büchler, Markus W. ; Friess, Helmut ; Herr, Ingrid. / Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. In: International Journal of Oncology. 2006 ; Vol. 29, No. 5. pp. 1295-1301.
@article{1c8a7f8a36bb44b6b5dbf5169e15b945,
title = "Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma",
abstract = "Glucocorticoids (GCs) such as dexamethasone (DEX) have been widely used as co-medication in cancer therapy because they have potent proapoptotic properties in lymphoid cells, can reduce nausea, and alleviate acute toxic effects in healthy tissue. However, GCs are used in a supportive-care role, even though no prospective clinical studies have assessed the effect of these steroids on the growth of solid tumours. Data from preclinical and, to some extent, clinical studies, suggest that GCs induce treatment resistance in some solid tumours. Since it is unknown whether GC-induced resistance occurs only occasionally or is a more common phenomenon, we performed a screening study using several established cell lines from bone, brain, breast and cervix carcinoma as well as melanoma and neuroblastoma together with fresh surgical resections from patients with breast cancer. We found that DEX inhibits cisplatin and 5-fluorouracil-induced apoptosis and promotes the growth of the majority of examined malignant cells. In contrast, and as expected, DEX acted pro-apoptotically and promoted the cytotoxic effect of chemotherapy in established and primary lymphoid cells. Thus, these data demonstrate the need for detailed molecular studies to clarify the mechanism of differential glucocorticoid signaling as well as controlled, prospective clinical studies.",
keywords = "Apoptosis, Cancer therapy, Glucocorticoids, Nausea",
author = "Chengwen Zhang and Benjamin Beckermann and Georgios Kallifatidis and Zheng Liu and Werner Rittgen and Lutz Edler and Peter B{\"u}chler and Debatin, {Klaus Michael} and B{\"u}chler, {Markus W.} and Helmut Friess and Ingrid Herr",
year = "2006",
month = "11",
day = "1",
language = "English (US)",
volume = "29",
pages = "1295--1301",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma

AU - Zhang, Chengwen

AU - Beckermann, Benjamin

AU - Kallifatidis, Georgios

AU - Liu, Zheng

AU - Rittgen, Werner

AU - Edler, Lutz

AU - Büchler, Peter

AU - Debatin, Klaus Michael

AU - Büchler, Markus W.

AU - Friess, Helmut

AU - Herr, Ingrid

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Glucocorticoids (GCs) such as dexamethasone (DEX) have been widely used as co-medication in cancer therapy because they have potent proapoptotic properties in lymphoid cells, can reduce nausea, and alleviate acute toxic effects in healthy tissue. However, GCs are used in a supportive-care role, even though no prospective clinical studies have assessed the effect of these steroids on the growth of solid tumours. Data from preclinical and, to some extent, clinical studies, suggest that GCs induce treatment resistance in some solid tumours. Since it is unknown whether GC-induced resistance occurs only occasionally or is a more common phenomenon, we performed a screening study using several established cell lines from bone, brain, breast and cervix carcinoma as well as melanoma and neuroblastoma together with fresh surgical resections from patients with breast cancer. We found that DEX inhibits cisplatin and 5-fluorouracil-induced apoptosis and promotes the growth of the majority of examined malignant cells. In contrast, and as expected, DEX acted pro-apoptotically and promoted the cytotoxic effect of chemotherapy in established and primary lymphoid cells. Thus, these data demonstrate the need for detailed molecular studies to clarify the mechanism of differential glucocorticoid signaling as well as controlled, prospective clinical studies.

AB - Glucocorticoids (GCs) such as dexamethasone (DEX) have been widely used as co-medication in cancer therapy because they have potent proapoptotic properties in lymphoid cells, can reduce nausea, and alleviate acute toxic effects in healthy tissue. However, GCs are used in a supportive-care role, even though no prospective clinical studies have assessed the effect of these steroids on the growth of solid tumours. Data from preclinical and, to some extent, clinical studies, suggest that GCs induce treatment resistance in some solid tumours. Since it is unknown whether GC-induced resistance occurs only occasionally or is a more common phenomenon, we performed a screening study using several established cell lines from bone, brain, breast and cervix carcinoma as well as melanoma and neuroblastoma together with fresh surgical resections from patients with breast cancer. We found that DEX inhibits cisplatin and 5-fluorouracil-induced apoptosis and promotes the growth of the majority of examined malignant cells. In contrast, and as expected, DEX acted pro-apoptotically and promoted the cytotoxic effect of chemotherapy in established and primary lymphoid cells. Thus, these data demonstrate the need for detailed molecular studies to clarify the mechanism of differential glucocorticoid signaling as well as controlled, prospective clinical studies.

KW - Apoptosis

KW - Cancer therapy

KW - Glucocorticoids

KW - Nausea

UR - http://www.scopus.com/inward/record.url?scp=33846477733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846477733&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 1295

EP - 1301

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -